AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results

About this update from Avita Medical, Inc.

[{"type":"image","alt":"AVITA Medical","displaySize":"","headline":null,"caption":"AVITA Medical","className":"","disableSlideshowImg":false,"size":{"original":{"width":96,"height":115,"url":"https://media.zenfs.com/en/globenewswire.com/dfd8c445a107185ef69e74538692859e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ejDr4RdwXqFCjMdbUOz.Ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/dfd8c445a107185ef69e74538692859e","width":96,"height":115}},"lazy":false},{"type":"text","content":"VALENCIA, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the fourth quarter and full year ended December 31, 2025.","length":313,"tagName":"p"},{"type":"text","content":"Fourth Quarter 2025 Financial Highlights and Recent Business Updates","length":68,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue of $17.6 million, compared to $18.4 million in the fourth quarter of 2024, reflecting the lingering impact of reimbursement headwinds throughout 2025.","length":164,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross profit margin of 81.2%, reflecting product mix and inventory-related adjustments.","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"Net use of cash improved for the second consecutive quarter to approximately $5.1 million, compared to $6.2 million in the third quarter, underscoring continued progress in cash efficiency.","length":189,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating expenses decreased 5% to $24.7 million, compared with $26.1 million in the corresponding period last year, reflecting a lower cost base.","length":146,"tagName":"p"}]},{"val":[{"type":"text","content":"Net loss of $11.6 million, or a loss of $0.38 per basic and diluted share, compared to $11.6 million, or a loss of $0.44 per share, in the fourth quarter of 2024.","length":162,"tagName":"p"}]},{"val":[{"type":"text","content":"In January, the Company announced the refinancing of its existing debt under a new credit facility with Perceptive Advisors LLC, securing up to $60 million of committed capital to strengthen the Company’s capital structure and support long-term growth."...

More updates from Avita Medical, Inc.